Alefacept. Biogen

Anthony Ormerod

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Alefacept is a lymphocyte function-associated antigen-3/IgG1 fusion protein that inhibits T-cells by antagonizing CD2, which has been developed and launched by Biogen for the potential treatment of psoriasis. In February 2003, Biogen launched alefacept in the US for use in adults with moderate-to-severe chronic plaque psoriasis, and by March 2003, the company was preparing for psoriasis trials to commence in Japan by the end of December 2003.
Original languageEnglish
Pages (from-to)608-613
Number of pages6
JournalCurrent Opinion in Investigational Drugs
Volume4
Issue number5
Publication statusPublished - 1 May 2003

Fingerprint

Psoriasis
CD58 Antigens
Japan
Immunoglobulin G
T-Lymphocytes
alefacept
Proteins

Keywords

  • Animals
  • Anti-Inflammatory Agents, Non-Steroidal
  • Antigens, CD58
  • Humans
  • Recombinant Fusion Proteins
  • Technology, Pharmaceutical

Cite this

Ormerod, A. (2003). Alefacept. Biogen. Current Opinion in Investigational Drugs, 4(5), 608-613.

Alefacept. Biogen. / Ormerod, Anthony.

In: Current Opinion in Investigational Drugs, Vol. 4, No. 5, 01.05.2003, p. 608-613.

Research output: Contribution to journalArticle

Ormerod, A 2003, 'Alefacept. Biogen', Current Opinion in Investigational Drugs, vol. 4, no. 5, pp. 608-613.
Ormerod A. Alefacept. Biogen. Current Opinion in Investigational Drugs. 2003 May 1;4(5):608-613.
Ormerod, Anthony. / Alefacept. Biogen. In: Current Opinion in Investigational Drugs. 2003 ; Vol. 4, No. 5. pp. 608-613.
@article{8ec3bce34afd4d86a9c3d21f49581174,
title = "Alefacept. Biogen",
abstract = "Alefacept is a lymphocyte function-associated antigen-3/IgG1 fusion protein that inhibits T-cells by antagonizing CD2, which has been developed and launched by Biogen for the potential treatment of psoriasis. In February 2003, Biogen launched alefacept in the US for use in adults with moderate-to-severe chronic plaque psoriasis, and by March 2003, the company was preparing for psoriasis trials to commence in Japan by the end of December 2003.",
keywords = "Animals, Anti-Inflammatory Agents, Non-Steroidal, Antigens, CD58, Humans, Recombinant Fusion Proteins, Technology, Pharmaceutical",
author = "Anthony Ormerod",
year = "2003",
month = "5",
day = "1",
language = "English",
volume = "4",
pages = "608--613",
journal = "Current Opinion in Investigational Drugs",
issn = "1472-4472",
publisher = "Current Drugs Ltd.",
number = "5",

}

TY - JOUR

T1 - Alefacept. Biogen

AU - Ormerod, Anthony

PY - 2003/5/1

Y1 - 2003/5/1

N2 - Alefacept is a lymphocyte function-associated antigen-3/IgG1 fusion protein that inhibits T-cells by antagonizing CD2, which has been developed and launched by Biogen for the potential treatment of psoriasis. In February 2003, Biogen launched alefacept in the US for use in adults with moderate-to-severe chronic plaque psoriasis, and by March 2003, the company was preparing for psoriasis trials to commence in Japan by the end of December 2003.

AB - Alefacept is a lymphocyte function-associated antigen-3/IgG1 fusion protein that inhibits T-cells by antagonizing CD2, which has been developed and launched by Biogen for the potential treatment of psoriasis. In February 2003, Biogen launched alefacept in the US for use in adults with moderate-to-severe chronic plaque psoriasis, and by March 2003, the company was preparing for psoriasis trials to commence in Japan by the end of December 2003.

KW - Animals

KW - Anti-Inflammatory Agents, Non-Steroidal

KW - Antigens, CD58

KW - Humans

KW - Recombinant Fusion Proteins

KW - Technology, Pharmaceutical

M3 - Article

C2 - 12833658

VL - 4

SP - 608

EP - 613

JO - Current Opinion in Investigational Drugs

JF - Current Opinion in Investigational Drugs

SN - 1472-4472

IS - 5

ER -